Equities

Myriad Genetics Inc

Myriad Genetics Inc

Actions
  • Price (EUR)25.00
  • Today's Change-0.40 / -1.57%
  • Shares traded200.00
  • 1 Year change+54.32%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 07:01 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments141115340
Total Receivables, Net11410291
Total Inventory222015
Prepaid expenses363838
Other current assets, total------
Total current assets314275485
Property, plant & equipment, net181187125
Goodwill, net287287239
Intangibles, net350380404
Long term investments05559
Note receivable - long term------
Other long term assets15168.30
Total assets1,1471,1991,321
LIABILITIES
Accounts payable262930
Accrued expenses10579146
Notes payable/short-term debt000
Current portion long-term debt/capital leases------
Other current liabilities, total252929
Total current liabilities156137204
Total long term debt3900
Total debt3900
Deferred income tax--3.5036
Minority interest--00
Other liabilities, total169172113
Total liabilities363313353
SHAREHOLDERS EQUITY
Common stock0.900.800.80
Additional paid-in capital1,4161,2601,226
Retained earnings (accumulated deficit)(630)(366)(254)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(3.7)(8.9)(5.1)
Total equity783886968
Total liabilities & shareholders' equity1,1471,1991,321
Total common shares outstanding908180
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.